Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 7/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18873650 | 0.88 | NAMPT (0.38) | EBPCHRM5ADRA2CKCNH2ACHE | |
| SCHEMBL15221483 | 0.86 | THRB (0.43) | CHRM5ADRA2CACHEALDH1A1THRB | |
| SCHEMBL3477990 | 0.84 | CHRM5 (0.48) | CHRM5ADRA2CACHEKDM4EALDH1A1 | |
| SCHEMBL17286004 | 0.83 | GBA1 (0.41) | EBPGBA1CHRM5ADRA2CKCNH2 | |
| SCHEMBL22520700 | 0.82 | ACHE (0.50) | CHRM5ADRA2CACHEKDM4EALDH1A1 | |
| SCHEMBL26480974 | 0.82 | ACHE (0.50) | CHRM5ADRA2CACHEKDM4EALDH1A1 | |
| SCHEMBL12188158 | 0.82 | ACHE (0.42) | EBPGBA1CHRM5ADRA2CKCNH2 | |
| SCHEMBL27423846 | 0.80 | CHRM5 (0.56) | CHRM5ADRA2CACHEKDM4EALDH1A1 | |
| SCHEMBL12950312 | 0.80 | CHRM5 (0.62) | CHRM5ADRA2CACHEKDM4EALDH1A1 | |
| SCHEMBL18682635 | 0.80 | CHRM5 (0.62) | EBPGBA1CHRM5ADRA2CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | EBP 2422/4885GBA1 3508/4885CHRM5 3220/4885 |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | MAOA, DRD2, MAOB | EBP 2805/4885GBA1 1662/4885CHRM5 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.